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SUMMARY 
,P.uRPosE: Antiphospholipid antibodies cause a prolongation of 
phospholipid dependent coagulation tests and a predisposi-
tion to thrombosis, recurrent fetal loss and other clinical 
manifestations. Lupus anticoagulants (LA) and anticardio-
lipin antibodies (ACA) are two forms of antiphospholipids 
present in high frequency in subjects with SLE. A plethora 
of different tests for LA have been described with few 
comparative studies available at the time of this study. 
The aims were to determine the prevalence of LA in a high 
risk group consisting of patients with SLE using a variety 
of tests and to determine the most appropriate procedure for 
routine laboratory use; to establish the frequency of ACA in 
this group and to analyse the association between antibodies 
to phospholipids and clinical complications . 
. PATIENTSMDME1HODS: A normal control group of 40 healthy staff 
members (20 males and 20 females) were tested using a full 
range of tests to determine normal ranges for platelet poor 
and filtered plasma. Seven positive control patients with 
SLE and previously confirmed LA were retested to evaluate 
the test methodology. A study group of 50 consecutive 
untreated patients with confirmed SLE attending the Lupus 
Clinic at Groote Schuur Hospital (48 female and 2 males; 
mean age 36.9 years) were tested for LA using centrifuged 
platelet poor plasma and filtered plasma by APTT, KCT and 
DRVVT tests and for IgG and IgM ACA by ELISA. Abnormal 
APTTs were subjected to 1:1 mixture tests for detection of 
inhibitors and confirmatory procedures PNP and TTI. 
iv 
RESULTS: Abnormal tests were defined as those values exceeding 
the 97.5% confidence interval of the normal range. Six 
(12%) of the SLE group exhibited LA activity. Moderate 
levels of IgG and IgM ACA antibodies were detected in 10 
(20%) and 26 (52%) respectively. Filtering of plasma 
produced a statistically significant prolongation of the KCT 
only without improving sensitivity. A history of clinical 
complications were recorded in 11 (22%) with 13 evaluable 
incidents. Six cases of recurrent fetal loss, two venous 
thromboses, one myocardial infarction, two neuropsychiatric 
disorders and one each of thrombophlebitis and pulmonary 
hypertension. 
CONCLUSIONS: The frequency of LA in patients with SLE was found 
to be quite low by current estimates. The APTT test and KCT 
were found to be equally sensitive in detecting the LA 
positive cases with the DRVVT positive in 66%. Filtering 
produced no improvement in test sensitivity. Confirmatory 
procedures (PNP and TTI) appear equally effective in 
confirming suspected cases. The ACA assay appeared to 
produce many spurious low titre positive results and thus 
only moderately elevated levels were taken into consider-
ation. ACA of the IgM isotype showed a strong correlation 
with LA positivity (83%) and occurred in 38% of patients 





Circulating anticoagulants or inhibitors of clotting are 
defined as endogenously produced substances that interfere 
with various in vitro tests of coagulation. 1 Specific 
factor inhibitors are usually immunoglobulins with epitope 
specificity for a single coagulation protein, the most 
frequent of which are auto or alloantibodies to factor VIII. 
Nonspecific inhibitors are antibodies which are not directed 
at any single coagulation factor but which interfere with in 
vitro coagulation tests and are not generally associated 
with bleeding. 
The lupus anticoagulant (LA) is a spontaneously acquired 
anticoagulant initially described in patients with systemic 
lupus erythematosus. 2 The term " lupus anticoagulant" was 
proposed by Feinstein and Rapaport in 1972 3 but is 
unfortunately a misnomer since the majority of patients do 
not suffer from systemic lupus erythematosus (SLE) and, in 
the absence of other haemostatic abnormalities, do not 
bleed. The LA was regarded chiefly as a nuisance by 
clinicians and laboratory researchers causing an unexplained 
prolongation of the partial thromboplastin time. 
Paradoxically, an increase in thrombotic events and/or a 
high rate of spontaneous pregnancy loss has been observed in 
patients in whom this laboratory abnormality appears.•-1• 
1.2 PATHOPHYSIOLOGY OF LUPUS ANTICOAGULANTS 
The lupus anticoagulant is an immunoglobulin of the IgG or 
IgM class (or a mixture of both) which may act by inhibiting 
the activity of phospholipid in clotting reactions. 
Characteristically, the antibody prolongs the partial 
thromboplastin time and fails to correct to normal upon 
mixing with equal volumes of normal plasma. 
Early studies of lupus anticoagulants emphasised the 
frequent association with false positive tests for syphilis, 
a reaction which depends on the presence of cardiolipin. 15 
and that the LA could be adsorbed by cardiolipin and Kahn 
antigen.16 This led to the understanding that lupus 
anticoagulants react with phospholipid but the precise 
epitope(s) are at present poorly defined. 
Pengo et al used affinity purification on cardiolipin 
liposomes followed by protein A-Sepharose chromatography to 
prepare phospholipid-free purified IgG LA from five patients 
to evaluate antibody specificity. 17 The purified lupus 
anticoagulant reacted with anionic phospholipids like 
phosphatidylserine (PS), phosphatidylinositol (PI) and 
phosphatidic acid (PA) but not with neutral phospholipids, 
phosphatidylethanolamine (PE) or phosphatidylcholine (PC). 
The lupus anticoagulants inhibited the calcium dependent 
binding of prothrombin and of factor X to cardiolipin and 
phosphatidylserine coated surfaces. These data support a 
common in vitro mechanism by which lupus anticoagulants bind 
to anionic phospholipids, thereby blocking the calcium-
2 
mediated assembly of vitamin K-dependent proteins to these 
coagulation-active surfaces. 
Recent research by Beavers et al has shown that expression 
of lupus anticoagulant activity requires the presence of 
anionic phospholipids, human prothrombin and calcium ions. 18 
The IgG antibodies showed a dose dependent inhibition of the 
prothrombinase activity in a system with human coagulation 
factors Xa, Va and prothrombin in the presence of lipid 
vesicles (20% PS and 80% PC). In contrast, no inhibitory 
effect was observed when human prothrombin was replaced by 
bovine prothrombin. The findings indicate that LA recognize 
an epitope which becomes exposed upon Ca-mediated binding of 
prothrombin to anionic phospholipids only in the presence of 
human prothrombin. LA should, therefore, be considered as a 
class of anti-prothrombin antibodies. Indeed, a high 
prevalence of anti-prothrombin antibodies has been reported 
for LA-positive plasmas, sometimes associated with low 
levels of prothrombin. 19 Our current understanding of the 
clinical significance of anti-prothrombin antibodies in 
patients with lupus anticoagulants confirms that they are 
non-neutralizing in nature and will not cause abnormal 
bleeding even when present in high titre. Clinical bleeding 
will only be encountered when the plasma is depleted of 
prothrombin as a result of accelerated clearance of 
prothrombin/prothrombin antibody complexes,19 
Watson & Schorer have demonstrated that lupus anticoagulants 
inhibit the in vitro release of prostacyclin in patients 
with a history of thrombosis. 20 Using cultured human 
3 
endothelial cells exposed to sera from patients with 
laboratory proven LA and antiphospholipid antibody activity, 
they showed that the release of prostacyclin was markedly 
inhibited in those patients with a recent history of 
arterial thrombosis. The effect was less in those with 
venous thrombosis and absent in patients with APA who had 
not experienced thrombosis. In this experimental model, 
thrombin is used as a secretologue, causing a 2.5 fold 
increase in prostacyclin secretion compared to basal 
production. Scherer et al have recently shown that LAs 
induce a selective defect in the thrombin mediated 
endothelial prostacyclin release without affecting thrombin-
mediated membrane inositol metabolism and total thrombin 
binding to endothelium.2 1 It must be noted that Watson & 
Schorer's results appear to be at variance with reports 
which found no inhibition of prostacyclin release in 
patients with SLE.22 In addition, lupus anticoagulants 
selectively blocked platelet aggregation with thrombin but 
not in response to arachidonate, ADP or epinephrine. 21 
The protein C/protein S/thrombomodulin system is an 
important anticoagulant system dependent on the endothelial 
membrane. Endothelial bound thrombomodulin is essential for 
thrombin-mediated activation of protein C in vitro. 1 Malia 
et al demonstrated that IgG antiphospholipid antibodies 
(LA/ACA) have an inhibitory effect on the activated protein 
C/protein S complex and provide some explanation for a 
relationship between APA and thrombosis,23 
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Thrombocytopenia is a common finding in patients with LA and 
thrombosis. One explanation is the activity of LA against 
platelet phospholipids which may damage blood platelets and 
increase their adhesiveness, thereby initiating thrombosis. 7 
1.3 CLINICAL ASSOCIATIONS 
The estimated incidence of lupus anticoagulants in patients 
with SLE ranges from 6 to 16% in earlier reports, 24 and 6 
to 73% (average prevalence: 34%) in a current review. 90 It 
may be found in a variety of other disorders, as a result of 
drug therapy and in apparently normal persons. 
Jude and colleagues published the clinical features in 100 
cases positive for lupus anticoagulant.2s Their findings 
are listed in the tables 1 and 2. 
Tab 7e 1. AUTOIMMUNE DISEASES ASSOCIATED WITH LA 






Chronic active hepatitis 
Goujerot-Sj~gren's syndrome 






Tab 1e 2. NON-AUTOIHHUNE PATHOLOGY ASSOCIATED WITH LA 
Neoplastic 
Uterus, breast, naevus, ovary, tongue, lip 
Haematological 
Waldenstr~m's disease, non-Hodgkin's lymphoma 





Pancreatitis, colic diverticulosis 
Cardiovascular 
Hypertension, coronaritis 




















Other examples of conditions giving rise to LA abound in the 
literature. For example, Yamazaki et a7 attributed 
transient induction of LA in a young woman to Epstein-Barr 
virus infection; 2s LA associated with primary malignant 
lymphoplasmacytic lymphoma of the spleen; 2s and induction 
by hydatidosis. 30 It remains to be seen if these findings 
can be substantiated by independent reporting. In some 
instances, no apparent underlying disease can be detected.13 
6 
Drug-induced LA has been reported with hydralazine, 
chlorpromazine, quinidine, phenytoin, penicillin and most 
commonly with the use of procainamide.2s 21 31 32 Long term 
use of chlorpromazine may be associated with the development 
of an IgM type LA with no apparent thrombotic 
predisposition.1 
Upper respiratory tract infections are frequently the cause 
of LA in children and detected as a result of preoperative 
coagulation screening performed prior to tonsillectomy or 
adenoidectomy. LA have been reported in 70% of patients 
with AIDS, 33 without clinical evidence of bleeding. There 
appears to be an association between infectious agents (eg 
Pneumocystis carinii) and the appearance of LA which 
disappear when the infection was satisfactorily treated. 34 
The finding of a LA is clinically noteworthy, because a 
prolonged APTT should not prevent a patient with AIDS from 
undergoing invasive procedures if no other coagulation or 
platelet abnormality is present,33 
1.4 COMPLICATIONS ASSOCIATED WITH LUPUS ANTICOAGULANTS. 
The clinical manifestations and complications seen in 
patients with lupus anticoagulants fall into two main 
categories namely venous or arterial thrombotic episodes and 
obstetric complications including spontaneous abortions and 
intrauterine fetal deaths. 
Thrombosis has long been recognized as a complication of SLE 
with the occurrence of leg vein thrombosis in up to 15% of 
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patients.2 Boey et al extended this observation in 1983 by 
reporting a striking association of thrombosis in patients 
with SLE and LA activity. 8 Testing a group of 49 patients 
with SLE and 11 other connective disorders, 31/60 were found 
to have LA activity; 25 of these had SLE. Thrombotic events 
were recorded in 18 of the 31 LA positive patients but only 
3/29 of the patients without LA gave a history of 
thrombosis. The wide ranging variation in frequency of LA 
reported in SLE (6 to 73%) 24 35 so may reflect fluctuation 
in the LA level with disease activity or treatment, but is 
more likely to reflect differing sensitivity of the various 
assays to detect lupus anticoagulants and lack of 
standardization.35 
The risk of a thrombotic event appears to be about 30% in 
patients with SLE 1 24 5 35 but may be as high as 68% in 
individuals with active disease and renal involvement . 36 
Wong and coworkers were unable to find any association with 
thrombosis in a recent study of 91 Chinese patients with 
SLE. 37 
The lower extremities are the most common site of venous 
thrombosis, while cerebral arteries are the most frequent 
site of arterial thrombosis. Manifestations of arterial 
thrombosis include stroke and transient ischaemic attacks,3B 
39 late-onset seizures,40 cerebellar ataxia,41 and ocular 
complications such as retinal artery occlusion, ischaemic 
optic neuropathy, transient visual loss or diplopia.42 
Myocardial infarction 12 43 4 4 is a recognized complication 
sometimes occurring in childhood.45 
8 
Skin manifestations described in patients with SLE and lupus 
anticoagulants are necrotic ulcers, livedo reticularis and 
pyoderma gangrenosum.46 Histologically the lesions are 
characterized by capillary angiogenesis with extravasated 
red blood cells, sparse inflammatory cell infiltrate and 
microthromboses, without evidence of vasculitis. In some 
cases the ulcers may resemble those seen in Degos' disease. 
Nilsson et al were the first to report the association 
between LA and intrauterine death,4 7 This finding has been 
confirmed by a number of other investigators. e 9 10 14 48 
49 so Fetal growth retardation, first trimester abortion 
and unexplained death in the second and third trimesters are 
more frequently seen in women with LA and/or anticardiolipin 
antibodies. The placentae in some cases may be found to 
have extensive infarction but the degree of impairment due 
to infarction in other cases does not appear to be 
sufficient to cause fetal demise. 6 9 Therefore, the 
relationship between placental thrombosis and fetal death 
remains unproven. 
The incidence of LA in patients with fetal loss varies 
considerably from 5% 49 to 48%,14 These women may represent 
a subset of patients who are risk of thrombosis as they may 
also frequently give a history of thromboembolic events.1 
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1.5 ANTIPHOSPHOLIPID ANTIBODIES (APA) 
Antibodies to cardiolipin are among various circulating 
autoantibodies found in SLE directed against complex lipid 
antigens. These antibodies are of the IgG, IgM or the IgA 
isotype. The association of a biological false positive 
test for syphilis in LA positive sera, is presumably based 
on the presence of antibodies cross-reacting against 
cardiolipin (the phospholipid antigen directed in standard 
test for syphilis), phospholipids in platelet membrane, and 
a phospholipid in the prothrombin activator complex of the 
coagulation cascade.s 1 Studies of this group of cross-
reacting antibodies had been limited by the relative 
insensitivity of precipitation tests. 
Harris et al in 1983 reported on a new solid-phase 
radioimmunoassay for the detection of anticardiolipin 
antibodies which was 200 - 400 times more sensitive than the 
precipitation method used in Venereal Disease Reference 
Laboratory test (VDRL).51 As the assay system has been 
shown to react with other negatively charged phospholipids 
(PS, PI, PA), the more generic term antiphospholipid 
antibodies was proposed.s2 In recent years, the enzyme-
linked immunosorbant assay (ELISA) has replaced RIA as the 
preferred technique in the detection of APA.so 11 Other 
potential advantages were that the tests could be done on 
sera rather than plasma, and results would be less affected 
by methods of preparation, transportation, and storage of 
specimens than the lupus anticoagulant test. In addition, 
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the anticardiolipin antibody test is not affected by 
concomitant anticoagulation treatment.55 
Antiphospholipid antibodies are associated with the same 
spectrum of clinical complications seen in LA positive 
patients namely arterial and venous thrombosis, recurrent 
fetal loss, thrombocytopenia and dermatological and 
neurological sequelae.48 53 They are also found in patients 
with AIDS.34 54 
The term 'Anti-Phospholipid (Anti-Cardiolipin) Syndrome' 
(APS),53 85 has been introduced to identify patients with 
persistently elevated levels of anti-cardiolipin antibodies 
or positive lupus anticoagulant tests, who are prone to 
complications. In an editorial in the Journal of 
Rheumatology, Hughes et al 53 summarized the clinical 
associations of the Anti-Phospholipid Syndrome as shown is 
Table 3. 
The first three clinical features are most frequently seen 
in association with the syndrome, but it is not always clear 
whether the other features are part of another underlying 
disorder, or whether they are related to the presence of 
anti-phospholipid antibodies.55 
The 'Primary' Antiphospholipid Syndrome se describes a 
subset of the above group, in which the patients have no 
features of lupus or who are classified as "lupus-like'', 
exhibiting less than 4 of the American Rheumatology 
Association Criteria for the diagnosis of SLE,57 
1 1 






Recurrent DVT (also axillary, IVC, and retinal 
vein thrombosis) 
Cerebrovascular accidents 
Peripheral arterial gangrene 
Coronary thrombosis 
Retinal artery thrombosis 
Pulmonary hypertension 
? Avascular necrosis 
Recurrent IUD, placental thrombosis, and 
infarction 
3. Thrombocytopenia 
Intermittent, often severe 






Chronic leg ulcers 
? Endocardial disease 
? Progressive dementia due to repeated 
cerebrovascular thromboses 
The reported incidence of ACA in patients with SLE has 
varied widely from 21 to 81 percent.ss The simultaneous 
_presence of ACA and LA in SLE has been reported as being 
positive in 91% of patients s1 while Triplett et al found 
71% of medical patients who have a prolonged APTT and LA to 
have ACA. In the latter group, the presence of ACA was not 
associated with an increased risk of thrombosis,59 Recently 
Barbara Alving and coworkers published results of a study on 
70 medical patient with prolonged APTTs. The ACA assay gave 
positive results in 47 patients, 44 of whom also tested 
positive for LA. Thus the sensitivity of the LA assay for 
detecting APA was 94%. Twelve of the 47 patients (26%) had 
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a history of venous or arterial thrombosis. Of these, 75% 
tested in the high-positive range for IgG or IgM ACA, or 
both. Of the 35 patients without thrombosis, only 14% were 
in this range. Patients with thrombosis have either 
underlying SLE, lymphoma or no apparent aetiology for LA. 
Thus determination of ACA levels in patients who have LA 
that is not induced by medication or infection may define 
those patients at increased risk for thrombosis.so 
The lack of concordance between the results of the various 
tests (which cannot be explained by differences in test 
sensitivity), has led most investigators to agree that anti-
phospholipid antibodies detected by one test need not be the 
same as those detected by another. 1 55 e1 Therefore, 
positive results for either the LA or ACA should be regarded 
as independent risk factors for thrombosis and both assays 
should be performed to maximize the likelihood of detecting 
antiphospholipids that may have clinical relevance.e2 
1.6 LABORATORY TESTS FOR LUPUS ANTICOAGULANTS 
1.6.1 DIAGNOSTIC CRITERIA 
Laboratory criteria for the diagnosis of lupus anticoag-
ulants remain a contentious issue, four decades after their 
initial description. The difficulty of evaluating patient 
samples for LA include the collection, transportation and 
processing of the blood sample which are very important in 
optimising laboratory detection of any coagulation 
abnormality. Care should be taken to avoid haemolysis or 
contamination by tissue fluid during collection of the 
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sample and the use of plastic or siliconised glass 
containers is recommended. The centrifugation step is 
critic~l, as the ability of coagulation assays to detect LA 
is inversely proportional to the number of platelets in the 
platelet poor plasma (PPP). The more platelet free the 
sample, the greater the sensitivity of most tests to the 
presence of LA. 63 It is particularly important to ensure 
the absence of platelets in PPP which is to be frozen for 
later testing, as freezing and subsequent thawing results in 
disruption of platelet with a release of phospholipids and a 
significant shortening of prolonged APTT values. Exner used 
Millipore R filters to prepare PPP and found enhanced 
sensitivity of both APTT and kaolin clotting time to LA.65 
Alternatively, the commercial serum-plasma separators allow 
preparation of excellent PPP (Sure-Sep,R Organon Teknika). 1 
The Working Party on Acquired Inhibitors of Coagulation of 
the International Committee on Thrombosis and Haemostasis 
proposed a set of criteria for the diagnosis of LA in 
1983. 66 They suggested the following: 
1. Prolongation of the APTT. 
2. The APTT of a 1:1 mixture with normal plasma should 
be greater than 4 seconds over the control. 
3; A d~crease in at least two factors (VIII, IX, XI,or 
XII) by one-stage assay, with normal values by two-
stage assay. 
4. A sensitivity to dilution, so that the apparent 
activity of the factor increases with dilution. 
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These criteria have proved to be too stringent, especially 
mixing studies which are difficult to interpret with mildly 
prolonged clotting times and factor assays which do not 
always show nonparallel curves. 1 Recent evidence suggests 
that a significant number of patients will be misdiagnosed 
using these criteria.ea 
It is generally accepted that the minimum criteria for 
diagnosis should demonstrate: 
1. An abnormality of phospholipid-dependent coagulation 
reaction(s) 
2. The abnormality is due to an inhibitor. 
3. Inhibitor activity is directed at phospholipid (not 
specific factors). 
Based on these criteria, the test system can thus be divided 
into (1) screening procedures to identify the coagulation 
abnormality; (2) procedures to demonstrate the inhibitory 
nature; and (3) a confirmatory procedure to identify 
phospholipid dependence. 
1.6.2 SCREENING PROCEDURES 
Lupus anticoagulants are most frequently detected in the 
laboratory by an unexplained prolongation of the activated 
partial thromboplastin time (APTT). This test has, 
therefore, become the preferred screening procedure. Until 
recently, reagent manufacturers did not consider the 
sensitivity of their APTT reagent to LA when marketing their 
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products. Considerable variation in the sensitivity of APTT 
reagents to LA have been documented 87 8 8 89 and it is 
important to select a reagent whose ability to detect weak 
LA has been proven. These differences are due to the choice 
of activator and to the nature and quantity of the 
phospholipids used as platelet substitute. In general, 
reagents with relatively low levels of phospholipids appear 
more sensitive to LA.1 10 
It has recently become apparent that two additional 
variables encountered in the detections of LAs need to be 
considered. They are the source and preparation of the 
reagents used in mixing studies and the dilution effect. 
Kaczor et al compared three commercially prepared reagents, 
Verify Normal citrate (Organon Teknika), Thromboscreen UCRP 
(Pacific Hemostasis) and Assayed Reference Plasma ARP 
(Helena) with an in-house reagent. The results showed 
Helena ARP to be the most sensitive commercial reagent 
producing the most prolonged APTT in mixing studies.11 To 
improve the sensitivity of the tests, it is important that 
the platelet-phospholipid content of the patient plasma and 
mixing reagent should both be as platelet-free as possible 
to enhance the LA effect. The dilutional effects will be 
explained in the next section. 
The Kaolin Clotting Time (KCT) is believed to be more 
sensitive to LA than a variety of other tests. 83 84 85 
Gastineau et al 2 4 found the plasma clot time (PCT) to be 
the most sensitive test for LA detection with a sharper, 
more reproducible end point. The disadvantage of the KCT 
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and PCT is that they are not readily automated or currently 
widely available. 1 These tests should be used to evaluate 
patients with a minimially prolonged APTT, or in patients 
with the antiphospholipid syndrome or with autoimmune 
diseases in whom the APTT is normal. 
A recent report by O'Neill et a7, describes an automated KCT 
developed to simplify screening for LA. The assay is 
performed on an Automated Coagulation Laboratory ACL 3000 
Research coagulation analyser, but may be modified for other 
centrifugal analysers. It has been difficult to automate 
the KCT as the opacity of the kaolin suspension interferes 
with a photo-optical determination of the clot end-point. By 
using a centrifugal analyser and modifying the strength of 
the kaolin suspension, it is possible to achieve an 
automated KCT.12 
Prothrombin time (PT) is relatively insensitive to LA 13 and 
not suitable as a screening test. This insensitivity to the 
inhibitor may reflect the amount of phospholipid in the 
reagent or its presence as a lipoprotein.1 When 
significantly prolonged, however, prothrombin deficiency 
should be suspected. 
1.6.3 IDENTIFICATION OF INHIBITOR ACTIVITY 
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' 
The use of mixing studies 'Y'e the first step to identify the JS 
presence of an inhibitor in the event of a prolonged APTT. 
A 1:1 ratio of patient plasma to normal pooled plasma is 
recommended 66 and the APTT is repeated. If the prolonged 
time fails to correct, the diagnosis of an inhibitor is 
confirmed. The definition of "failure to correct" is not 
clearly defined and may vary depending on the degree of 
prolongation of the initial APTT. 
Mixing studies in a minimally prolonged APTT (<7 seconds 
longer than the control time) are difficult to interpret as 
distinction of a correction from a dilution effect may be 
problematic.1 es In these instances, the use of a 4:1 ratio 
of patient plasma to mixing reagent is more sensitive than 
the commonly used 1 :1 ratio.11 
Occasionally mixing studies on a patient with LA may yield a 
time which is much longer than the initial APTT. This 
paradoxical finding is seen .i.s test systems with low 1i1 
phospholipid concentrations and is due to the lupus 
cofactor.1 24 11 74 Laboratories which utilize a 4:1 
mixture will observe the cofactor effect more often than 
those employing a 1:1 mix. The substance present in normal 
plasma which accounts for the cofactor effect is unknown. 
An alternative procedure for the detection of inhibitors is 
the use of plasma agarose gels. A modified method which is 
particularly suited to detect lower titre inhibitors, wai 
described by Cassidy et al. 1s The results are reproducible 
and precise and interpretation is unambiguous. The test 
system is positive for any type of circulating anticoagulant 
(heparin, factor VIII inhibitor, LA) and thus further 




With the exception of a rare dissenting opinion 76 there is 
general agreement that LA are immediate acting, that is, 
they do not require incubation to demonstrate maximal 
anticoagulant activity. This characteristic is often 
contrasted with factor VIII inhibitors, especially those of 
low avidity, which frequently require incubation to be 
detected.11 In a retrospective study, Clyne and White 
showed that in 60% of cases the theory was indeed 
vindicated. In the remaining 40% of cases, however, a time 
dependent pattern was evident where the 60-minute ratio 
exceeded the increment predicted to occur through 
variability. The authors conclude that many potent LA 
require incubation to maximimally express anticoagulant 
activity and this activity might not be detected if mixing 
studies are restricted to the preincubation phase.77 
1.6.4 CONFIRMATORY PROCEDURES: 
IDENTIFICATION OF PHOSPHOLIPID DEPENDENCE 
Two approaches may be use to document phospholipid 
dependence. The first utilizes the inverse relationship 
between the phospholipid content and the degree of pro-
longation. Tests in this group include tissue thrombo-
plastin inhibition test (TTP), dilute Russell Viper Venom 
Test (DRVVT), the dilute phospholipid APTT (DL-APTT) and the 
KCT. The reduction of phospholipid in these tests 
accentuates the LA induced prolongation. The second 
approach is through neutralization of the inhibitor effect 
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by increasing the phospholipid content ie the platelet 
neutralization procedure (PNP). 
1.6.4.1 TISSUE THROMBOPLASTIN INHIBITION TEST (TTI) 
This test was first described by Schleider et al 18 and is 
based on a dilute prothrombin time using Simplastin R 
reagent in a dilution of 1:50 and 1:500. The results are 
expressed as a ratio of patient to normal with a value of 
>1.3 being abnormal. As the test is sensitive but not 
specific for LA 79 so it should not be used alone to confirm 
the diagnosis. False positives results have been seen in 
normal subjects (30%), specific factor inhibitors, 
hereditary coagulation deficiencies and in patients 
receiving warfarin or heparin.1 
1.6.4.2 DILUTE RUSSELL VIPER VENOM TIME (DRVVT) 
This test can be used both as a sensitive and specific 
screening procedure and as a confirmatory test for LA. 
Originally described by Thiagarajan et al, this test uses a 
dilute source of phospholipid with a predetermined dilution 
of Russell's viper venom to give a normal range of 25 to 28 
seconds. 81 This test has found wide favour 74 s2 and was 
found to be significantly associated with thrombotic events 
in one study.35 A disadvantage is that the DRVVT is not 
easily automated and, therefore, the DL-APTT is more widely 
used. 
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1.6.4.3 DILUTE PHOSPHOLIPID APTT (DL-APTT) 
This simple and sensitive method for the verification of LA 
utilizes dilution of phospholipid in the activated partial 
thromboplastin time system. Patient plasma, mixed with an 
equal volume of normal plasma, is activated with micronized 
silica. To this mixture are added different dilutions of 
Thrombofax Rand then calcium chloride. Clotting times are 
plotted linearly against the logarithm of the phospholipid 
dilution and slopes are calculated by regression analysis. 
The advantage of this assay is that LA can be monitored in 
patients on warfarin or heparin therapy.e3 
Alving and co-workers have modified and simplified their 
original method utilizing a one-point dilute phospholipid-
APTT expressed as a ratio of the a mixture of normal and 
patient plasma to that of normal plasma alone. Standardized 
preparations of phosphatidylcholine/phosphatidylserine 
(PC/PS) was substituted for bovine thromboplastin 
(Thrombofax). 84 A positive test for LA was defined as a 
ratio of ~1.3 with liposomes and ~1.2 with Thrombofax. In a 
comparison between their modified DL-APTT and a similarly 
modified RVVT, they demonstrated higher sensitivity of the 
DL-APTT and greater specificity of the RVVT in detecting LA. 
1.6.4.4 PLATELET NEUTRALIZATION PROCEDURE (PNP) 
The PNP is a useful test to confirm the diagnosis of LA. It 
was first described by Triplett et a7 in 1983 79 and is 
based on earlier observations by Exner 63 of the ability of 
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platelets to bypass the LA or significantly correct 
prolonged clotting times. Outdated frozen and thawed 
platelets are added to patient plasma and APTT reagent. 
There is a significant shortening of the APTT if LA are 
present, whereas a factor specific inhibitor plasma is not 
shortened. The test is highly specific in this regard as 
alluded to in several reports,24 79 A commercial source of 
platelets is now available (Platelet Extract Reagent, R Bio-
Data Corporation). 
1.6.4.5 OTHER CONFIRMATORY TESTS: FACTOR ASSAYS 
The ICTH Working Party on Acquired Inhibitors of Coagulation 
indicated that assays of factors of the proximal intrinsic 
pathway may need to determined to confirm the diagnosis of 
LA. Typically, two or more will show diminished activity, 
with greater dilutions of patient plasma showing a higher 
apparent factor activity giving rise to non-parallel curves. 
Factor activity using two-stage assays will be normal.&& 
1.6.5 STANDARDIZATION OF CRITERIA FOR THE DIAGNOSIS OF LA 
The clinical diversity of the primary antiphospholipid 
syndrome has recently become widely recognised 85 and the 
identification of the LA is important in the diagnosis and 
management of this condition. Consequently lupus 
anticoagulant testing has become an essential routine 
procedure for haemostasis laboratories. Nevertheless, there 
is considerable controversy about the most appropriate 
methods for detecting LA.87 
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Dissatisfaction and frustration with the criteria for the 
diagnosis of LA has led to the appearance in 1991, of 
guidelines for standardization of lupus anticoagulants from 
parties on opposite sides of the world. 
1.6.5.1 BCSH LA GUIDELINES 
The Lupus Anticoagulant Working Party, of behalf of the BCSH 
Haemostasis and Thrombosis Task Force of the British Society 
for Haematology, published guidelines on testing for the 
lupus anticoagulant in November, 1991. 67 The report is 
based on the findings of the first and second United Kingdom 
Lupus quality control survey conducted in 1987 and 1988. As 
a result of these observations, standardised methodological 
guidelines for laboratories wishing to test for the presence 
of LA were formulated. The recommendations are given 
briefly below. 
Any definition of the lupus anticoagulant must include 
the phospholipid dependency of the inhibitory activity 
in clotting testing and the relative correction by 
lysed platelets or increased phospholipid concent-
ration. (Table 4) 
Tab7e 4. CRITERIA FOR LUPUS ANTICOAGULANT 
1. Prolongation of a phospholipid dependent clotting test 
2. Clotting time of a mixture of test and normal plasma 
should be longer than the clotting time of normal plasma 
3. There should be a relative correction of the defect by 
the addition of lysed platelets or phospholipids 
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The preanalytical conditions with regard to sample 
collection and handling were specified. Minimal stasis 
to avoid platelet activation; processing of sample 
ideally within one hour of collection; and double 
centrifugation or filtration to obtain platelet 
depleted plasma (<10 x 1os;1) were the main 
recommendations. 
similar way to 
specifications). 
Control plasma must be prepared in a 
test plasma (or check manufacturers 
It is recognised that the inhibitors are heterogeneous 
in their behaviour in phospholipid dependent 
coagulation tests and no single test is sufficient. At 
least two are advisable, one of which could be the 
screening test (APTT). 
A coagulation screen including PT, APTT, with TT or 
fibrinogen estimation is required to exclude 
abnormalities unrelated to LA. A flow diagram for the 
laboratory investigation of LA is given in Figure 1. 
The APTT should be performed on freshly prepared PPP, 
on pooled normal PPP and on a mixture of four parts 
patient PPP and one part normal PPP (4:1 mixture). 
It is important that consideration be made of the 
clinical situations in which screening for LA may be 
indicated (thrombosis, fetal loss, SLE, ITP, livedo 
reticularis and false positive test for syphilis and 
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General coagulation screen 
including: APTT, PT, TT(FIB) 
' Prolonged APTT 
l 
APTT mixture (4:1) 
Abnorm~al Normal ...__ 
--... ? Spec i fic coagulation 
\
Strong clinical factor defect 
features 
~ ~ ~ 
Ratio >1.2 <1.1 Ratio <1.1 >1.1 
l l l l 
Abnormal Normal Normal Abnormal 
Figure 1. FLOW DIAGRAM FOR LABORATORY INVESTIGATION WHEN 
LUPUS ANTICOAGULANT IS SUSPECTED. 
To confirm the presence of LA, two positive resu1ts are 
advisab7e, of which one may be the screening APTT. 
(After Machin et a1 67). 
undue sensitivity of APTT to heparin therapy), as even 
the most sens i ti ve APTT method w i 11 not detect a 11 
inhibitors and so an additional specific test should be 
preformed in suspected cases of LA, even if the APTT is 
normal. 
Confirmatory tests demonstrate that the inhibitor 
activity of LA are directed against procoagulant 
phospholipids. Standardised methodologies for the 
recommended tests, KCT and DRVVT, are supp 1 i ed in the 
text.67 
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1.6.5.2 SSC LA GUIDELINES 
The Scientific and Standardization Committee (SSC) 
Subcommittee for the Standardization of Lupus Anticoagulants 
published Guidelines of Testing and Revised Criteria for 
Lupus Anticoagulants in March, 1991.ee (Table 5) 
Tab7e 5. REVISED SSC CRITERIA FOR LUPUS ANTICOAGULANTS 
1. Prolongation of phospholipid-dependent clotting tests 
i.e. kaolin clotting time (KCT), dilute Russell's viper 
venom time (DRVVT), tissue thromboplastin inhibition test 
(TT!), plasma recalcification time (RCT) or a sensitive 
APTT. 
2. Clotting time of a mixture of test and normal plasmas 
should be significantly longer (i.e. more than 3 standard 
deviations) than that of the normal mixed and various 
non-LA patient plasmas. 
3. There should be a relative correction of the defect by 
the addition of lysed, washed platelets or preferably 
phospholipid liposomes containing phosphatidylserine or 
hexagonal phase phospholipids. 
4. Other criteria for LA include: Non-specific for any 
individual clotting factor, rapidly losing apparent 
activity on dilution of test plasma with saline (i.e. 
giving non-parallel lines in factor assays), usually fast 
acting and associated with positive antiphospholipid 
antibody ELISA's. The anticoagulant should be identified 
as an immunoglobulin whenever possible (stable at 56"C 
for 20 minutes, protein G extractable, etc). 
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CHAPTER 2 
AIMS _OF_THE . PROJECT 
The idea for this project was conceived in 1987 when the 
guidelines for the investigation of lupus anticoagulants 
required further definition and refinement. A plethora of 
different tests were being reported in the medical 
literature with very few comparative studies available. It 
was imperative that the various methods of investigating 
lupus anticoagulants be examined and compared, so that 
recommendations could be made regarding the most suitable 
tests for confirming this laboratory phenomenon and applying 
them to routine testing in a haematology laboratory. 
In a attempt to clarify understanding of the lupus 
anticoagulant, it was necessary to study a uniform well 
managed population in which there was a good statistical 
chance of detecting this inhibitor in high frequency. 
Patients with clinically proven systemic lupus erythematosus 
were selected as test group with the aim of establishing the 
incidence of lupus anticoagulants and anticardiolipin 
antibodies. In view of the suggested heterogeneity of the 
antibody, a variety of different tests for their detection 
were used to determine the sensitivity and specificity of 
each procedure. 
A retrospective study of the correlation between antibodies 
to phospholipids and the occurrence of clinical manifest-
ations such as arterial and venous thrombosis and 
27 
spontaneous fetal loss occurring and other related problems, 
was undertaken in this study group. 
A group of normal controls were tested using the same test 
procedures to establish the normal range for each variable. 
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CHAPTER 3 
MATER.IALS._AND _ METHODS 
3.1 STUDY GROUPS 
The SLE study group was drawn from the Lupus Clinic at 
Groote Schuur Hospital in Cape Town. It comprised fifty 
consecutive adult patients attending the out-patients clinic 
over a six month period between April and November 1988. 
There were 48 females and 2 males in the group and all 
fulfilled at least four the 1982 American Rheumatism 
Association (ARA) revised criteria for the diagnosis of 
systemic lupus erythematosus. 5 7 None of the patients was 
receiving immunosuppressive treatment for active SLE at the 
time of testing or during the preceding four weeks and none 
were on any anticoagulant therapy. 
The control group was made up of forty healthy members of 
staff of the Haematology Department, Groote Schuur Hospital, 
consisting of an equal number of males and females from both 
white and mixed racial groups. 
A positive control group, consisting of patients with 
previously diagnosed lupus anticoagulants, were retested 
using the proposed laboratory procedures to establish the 
methodology. Laboratory records were examined and all 
available LA positive patients were contacted. Seven 
patients agreed to retesting. 
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Informed consent was obtained from patients and controls, in 
keeping with the policies of the Ethics and Research 
Committee of the Groote Schuur Hospital and the Faculty of 
Medicine, University of Cape Town. 
3.2 BLOOD COLLECTION AND SAMPLE HANDLING 
Fifteen millilitres of whole blood was collected by 
venepuncture using a 19 gauge butterfly and two syringe 
technique. Meticulous attention was taken to ensure 
adequate blood flow and to avoid aspiration of any tissue 
fluid. Blood was anticoagulated with 3.8% trisodium citrate 
in the ratio of one part anticoagulant to 9 parts of blood 
and placed in plastic containers. 
Platelet poor plasma was prepared following centrifugation 
at 2500g for 15 minutes at room temperature. Plasma samples 
were tested immediately and aliquots were also stored in 
polystyrene tubes, quick frozen and kept at -1o·c. A 5ml 
sample of clotted blood was taken at the time of 
venepuncture and following centrifugation, aliquots of serum 
were stored in similar containers and storage conditions 
until tests for anticardiolipin antibodies were performed. 
Filtered plasma was prepared on test and normal groups by 
passing aliquots of platelet poor plasma through a 0,22 µm 
Millipore R type GS cellulose acetate filter in stainless 
steel screw-together assemblies. 
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3.3 CLOTTING TESTS 
Pro thrombi n_ ti me __ i.PT) 
The one-stage prothrombin time was determined using acetone 
dried human brain thromboplastin, prepared in accordance 
with the technique described by Giddings (in Thompson),87 
and of known International Sensitivity Index (!SI). 
Activated Partial Trombo.Rlastin Time .{APTT) 
Tests were carried out with 0,1 ml of auto-APTT reagent 
(General Diagnostics, Morris Plains, New Jersey) (presently 
manufactured by Organon Teknika) preincubated for 5 minutes 
and subsequently timed to a clotting endpoint after the 
addition of 0,1 ml of 0,025M calcium chloride in an X2 
photoelectric coagulometer (General Diagnostics USA). 
Samples showing a prolongation of the APTT by >5 seconds 
over the upper limit of the control series, were screened 
for the presence of an anticoagulant. This screening 
procedure consisted of performing an APTT by mixing equal 
volumes of patient and normal plasma (General Diagnostics, 
Verify Normal R Coagulation Control plasma). Failure of 
normal plasma to correct the prolonged APTT to within 4 
seconds of the normal range, indicated the presence of a 
circulating inhibitor. These samples were subjected to two 
confirmatory tests: 
(a) Platelet neutralization procedure and 
(b) Thromboplastin inhibition test 
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Pl ate let neutral i_zat i_on_pyocedure 1.PNP J 
This test was performed as described by Triplett and 
colleagues.1s A newly expired unit of platelet concentrate 
(Western Province Blood Transfusion Service, Cape Town) was 
aliquotted into smaller volumes, washed three times in Tris 
buffered saline and 3 ml aliquots containing 200 - 300 x 
1os;1 platelets were frozen at -1o·c until further use. 
A mixture of auto-APTT reagent (General Diagnostics), 
patient's plasma and thawed platelet suspension was 
incubated at 37°C for 5 minutes then 0,025M CaCl2 was added 
and time to clot formation determined in duplicate. A 
baseline APTT minus PNP APTT of >5 seconds was considered 
positive. 
PNP results in a shortening of the clotting times of 
specimens with lupus anticoagulants from the baseline APTT 
with a median of 10 seconds (range 4 to 78 seconds). In 
general, the longer the initial APTT, the greater the 
shortening with the PNP. In contrast, there is no 
shortening of the PNP APTT in most patients with specific 
factor inhibitors. 
Tissue thrombo_p.l ast in __ i nhi.bi t .i on _test _J .TTIJ 
In 1976 Schnleider and associates introduced the concept of 
dilute thromboplastin test and suggested that it was a 
useful procedure for diagnosis of LAs.1a However, it was 
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shown by Triplett not to adequately differentiate LAs from 
specific factor inhibitors or to the presence of heparin. 79 
In view of the long standing use of the test in the study of 
lupus anticoagulants, it was evaluated in this study as a 
confirmatory procedure. 
Acetone dried human brain thromboplastin was diluted 1:50 
and 1:500 with normal saline (0,9%) and incubated at 37°C 
for 5 mins. 0,1 ml of diluted thromboplastin was added to 
0,1 ml of patient plasma and the mixture incubated at 37°C 
for 5 minutes. 0,1 ml of 0,025M calcium chloride was then 
added to the mixture and the clotting times measured. The 
ratio of clotting times at 1:100 and 1:1000 dilutions was 
then determined. A ratio of 1,3 or greater was considered 
positive and indicative of a lupus anticoagulant. 
S~cific_ factor __ assa_ys ____ of .... the i ntrinsic __ ..Qathw~ 
Two factor assays of the intrinsic pathway (factors VIII and 
IX) were performed to rule out concurrent specific factor 
inhibitors using reagents and methodologies recommended by 
the manufacturer of the Automated Coagulation Laboratory 
(ACL) 800 centrifugal coagulation analyser (Instrumentation 
Laboratories, Milan). LAs characteristically give non-
parallel curves with greater inhibition at higher dilutions. 
Kaolin clotting_ time 
This test was performed as originally described by 
Margolis 88 using 0.1 ml plasma preincubated for 3 minutes 
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in a water-bath at 37 °C with 0.05 ml kaolin (20mg/ml in 
Owren's buffer, pH 7.35) and then recalcified with 0.1 ml 
0.25 M calcium chloride. The manual tilt tube method was 
performed in duplicate on each sample of PPP and filtered 
PPP. Times were considered abnormal if prolonged beyond the 
upper limit of the normal range established for this test 
(>106 s). An alternative evaluation scheme is the 
calculation of a ratio. 
A test ratio: test .. - (seconds) 
normal (seconds) 
of more than 1.2 indicates an abnormal result. A normal 
ratio is less than 1.1 and values in between are considered 
borderline. 
A control time of less than 60 seconds suggests 
contamination of the normal control plasma by platelet 
fragments, and invalidates the results. 
Di 1 ute Russe 11. 's .... V...1.Rer . Venom Test .. J DRVVT) 
The DRVVT was performed as previously described by 
Thiagarajan et al 81 using Russell's viper venom (Wellcome 
Diagnostics) reconstituted as suggested by the manufacturer 
and further diluted 1:200 in Tris-buffered saline to give a 
clotting time of between 25 and 30 seconds. The phospho-
lipid reagent was diluted 1:8 in Tris-buffered saline. The 
test was performed by incubating 0.1 ml of plasma, 0.1 ml of 
diluted RVV, and 0.1 ml diluted phospholipid for 30 seconds 
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at 37·c after which 0.1 ml of calcium chloride was added and 
the clotting time recorded. 
A clotting value of >3.8 SD above the mean is considered 
abnormal by Thiagarajan et al. This corresponds to 
approximately four seconds above the mean. 
3.4 ANTICARDIOLIPIN ANTIBODY (ACA) TESTING 
Sera for performing this assay were frozen and stored for 
later batch testing. The assay was performed using a 
modification of the ELISA method described by Lockshin et 
al. so eg Cardiolipin (Sigma St. Louis, MO) was used as 
substrate. Results were standardized to a single positive 
serum sample. Arbitrarily, 100 units of reactivity 
corresponded to the reaction produced by 20 µl of this 
serum. Significant levels were defined as 4 standard 
deviations (SD) higher than the mean of the normal controls 
(described previously). 
The OD (optical density) values were interpreted as follows: 
High positive > 100 units IgG 
> 60 units IgM 
Moderate positive 15 - 100 units IgG 
6 - 60 units IgM 
Low positive 5 - 15 units IgG 
3 - 6 units IgM 
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The VDRL test was performed on all patients samples to 
eliminate cross-reactivity between positive ACA and 
syphilis. All positive VDRLs were FTA negative and 
therefore considered to be biological false positives. 
3.5 STATISTICAL METHODS 
An analysis of the normal range and patients data was 
performed using the upper 97.5% confidence interval 
(x + 1.96 x SEM) to determine the out of normal range for 
each variable. An univariate analysis was performed on the 
whole sample to establish those with abnormal values. The 
Student t test was used to determine the significance of 





4.1 ESTABLISHMENT OF THE NORMAL RANGE 
Clotting times of the tests performed on forty normal 
controls using platelet poor and filtered plasma, is shown 
in Table 6. 
Platelet counts were determined on all 40 plasma samples 
after centrifugation and post-filtration using a Coulter 
S-Plus blood count analyzer. The mean platelet count of PPP 
was 23.77 x 109 /1 (SD 11.09) and 11.03 x 109 /1 (SD 7.33) for 
the post-filtration samples. This difference is statistic-
ally significant (p <0,000001 ). 
The values in Table 6 were analyzed statistically and the 
results comparing the two variables are given in Table 7. 
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Table 6. FORTY NORMAL CONTROLS USING PPP AND FILTERED 
PLASMA WITH VALUES SHOWN IN SECONDS (EXCEPT INR). 
----------------------------------------------------------------------------------------
CENTRIFUGED PLATELET POOR PLASMA FILTERED PLASMA 
----------------------------------------------------------------------------------------
No. SEX INR APTT APTT KCT KCT DILUTE DRVVT I INR APTT KCT DRVVT I 
CONTROL CONTROL RVVT CONTROL I I 
----------------------------------------------------------------------------------------
1 M 1.05 33 30 96 68 27 29 1.09 34 166 30 
2 F 1.01 30 30 79 68 29 29 0.89 33 161 30 
3 F 1. 10 30 31 83 58 27 26 1.03 30 134 28 
4 M 1.10 29 31 83 58 29 26 1. 17 31 154 31 
5 F 0.93 29 32 69 71 29 28 0.94 35 107 30 
6 M 1.04 27 32 82 71 26 28 1.05 29 152 28 
7 M 0.97 31 32 86 63 35 32 0.98 32 174 34 
8 F 1 32 32 109 63 34 32 0.98 34 192 34 
9 F 1.01 33 32 84 76 26 26 1.02 36 196 27 
10 M 1.04 29 32 82 76 28 26 1.11 32 175 28 
11 F 1.02 28 32 74 83 26 26 1.05 33 109 26 
12 M 1.03 27 32 82 83 27 26 1.02 29 137 27 
13 F 1. 11 35 32 110 87 25 27 1. 15 40 225 25 
14 M 1.06 24 32 72 87 25 27 1. 12 27 130 26 
15 M 0.98 25 31 69 76 30 28 1.03 27 119 30 
16 M 1. 10 33 31 102 76 31 28 1. 13 37 211 31 
17 F 1. 11 25 31 66 82 28 30 1.10 25 61 28 
18 F 1.01 29 31 71 82 27 30 1.02 32 149 27 
19 M 1.04 28 31 69 82 29 30 1.05 31 143 27 
20 M 1. 06 31 31 72 82 29 30 1.05 34 143 33 
21 F 1.08 36 31 95 81 30 28 1.10 36 137 30 
22 M 1.01 31 31 83 81 28 28 0.93 33 136 30 
23 F 0.96 27 31 80 81 31 28 0.98 28 127 29 
24 M 1.02 31 31 80 81 31 28 1.02 32 143 30 
25 F 0.83 30 34 83 81 27 27 1 30 86 27 
26 M 1.05 27 34 80 81 29 27 1.04 28 128 29 
27 F 1. 16 29 34 86 81 27 27 1.16 31 152 27 
28 M 1. 13 32 34 110 81 28 27 1. 12 33 186 27 
29 F 1.08 30 33 85 85 29 28 1.02 30 178 29 
30 M 0.96 27 33 76 85 29 28 1 27 108 30 
31 F 1 32 31 72 81 29 30 1 32 155 30 
32 F 1.1 29 31 82 81 29 30 1. 1 31 165 31 
33 M 1 29 31 90 81 30 30 1 31 177 30 
34 M 1.1 28 31 73 81 30 30 1. 1 30 141 32 
35 M 1 26 30 73 80 32 27 1 26 110 32 
36 F 1 33 31 64 85 27 27 1 36 146 29 
37 F 1 26 34 44 81 21 29 1 28 76 24 
38 F 1.04 33 34 68 81 34 29 1.07 35 129 33 
39 M 1. 14 34 34 82 81 27 29 1. 17 44 168 32 
40 F 1 32 34 74 81 30 29 1 35 140 34 
----------------------------------------------------------------------------------------
Mean: 1.03 29.75 31.87 80 .5 78.07 28.63 28.25 1.04 31.92 145.65 29.37 
----------------------------------------------------------------------------------------
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The out of range values were calculated using the 97.5% 
confidence interval of the normal distribution curve for 
each variable. The values used in this study are: 
APTT .............. > 35.377 s 
KCT .............. >105.959 s 
DRVVT ............. > 33.738 s 
I NR . . . . . . . . . . . . . . > 1 . 160 
Filtered APTT ..... > 39.423 s 
Filtered KCT ...... >212.811 s 
Filtered DRVVT .... > 34.251 s 
Filtered INR ...... > 1.176 
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Filtering of plasma produced af significant difference in )( 
the KCT only (p <0.000001). This prolongation in test time 
is attributed directly to the removal of platelets as source 
of phospholipids. 
4.2 ABNORMAL CONTROLS 
Seven known lupus anticoagulant positive patients were 
retested using APTT, KCT and DRVVT. The results shown in 
Table 8, reflect a prolonged APTT in six with an uncorrect-
able 1:1 mixture of patient and normal plasma. 
Table 8. CLOTTING TESTS PERFORMED ON ABNORMAL CONTROLS. 
No. INR APTT APTT KCT DRVVT 
MIX 
1 1 . 1 46 40 124 25 
2 1.3 73 44 149 30 
3 1 . 1 52 42 140 33 
4 1 . 1 54 45 94 39 
5 1 . 1 59 53 138 43 
6 1 . 2 58 45 137 37 
7 1 . 0 35 31 103 44 
Control 1 . 0 32 79 29 
The INR was abnormal in patients 2 and 6. In our laboratory, 
however, the normal range accepted for this test is 1.0 to 
1. 3. 
The KCT was out of range in all except nos. 4 and 7 using 
106 seconds as upper limit of normal. This result was 
compared with the KCT ratio obtained by dividing test time 
by control time and expressing the result as a ratio 
described by Machin et a1.s1 A value of >1.2 is regarded as 
abnormal. 
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The ratio obtained for patient no. 4 is interpreted as being 
borderline (values >1.1 but less than 1.2). 
The DRVVT was abnormal in patients 4, 5, 6 and 7 ( ~34 s). 
This was compared with the DRVVT ratio where a value of >1.1 
is abnormal. 
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Five of the ratios were abnormal using this calculation, 
including the borderline case no . 3. 
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Filtration of the plasma (data not shown) produced no 
difference in interpretation of the results of these seven 
patients. 
4.3 SLE PATIENT GROUP 
Coagulation tests were performed on fifty consecutive 
untreated patients with systemic lupus erythematosus. There 
were 48 females and 2 males with a mean age of 36.9 years 
(range 22 to 54 yrs). Results are shown in Tables 9 and 10. 
In the PPP group, 10 APTTs (20%) were abnormal but only 6 
(12%) fulfilled the ICTH criterion: The APTT of a 1:1 
mixture with normal plasma should be greater than 4 seconds 
over the control, 6 6 (i.e. 32 + 4 s). Eight KCT (16%) and 
five DRVVT (10%) results were abnormal. 
Using filtered plasma (Table 10), 6 APTTs (12%) were out of 
range with four (8%) failing to correct on mixing with 
normal plasma. Seven KCT (14%) and three DRVVT (6%) results 
were abnormal. 
The six plasma samples with prolonged APTT mixtures 
identified in the PPP group, were subjected to confirmatory 
procedures listed in Table 11 and to factor VIII and IX 
assays. The PNP confirmed the diagnosis of lupus 
anticoagulant in 4 of the 5 tested. Patient no. 29 failed 




Tab1e 9. COAGULATION RESULTS ON FIFTY SLE PATIENTS USING 
PLATELET POOR PLASMA. 
------------------------------------------------------------
NO. SEX AGE INR APTT 1 : 1 KCT DRVVT 
MIX 
------------------------------------------------------------
1 F 22 1 27 61 28 
2 F 31 1 . 1 2 28 80 28 
3 F 35 0.97 24 63 30 
4 F 53 1 . 13 31 79 28 
5 F 51 1.04 26 82 30 
6 F 43 1.02 30 83 27 
7 F 33 1. 24 § 29 82 26 
8 F 25 1 . 1 9 § 31 90 27 
9 F 26 1 . 1 1 39 § 35 99 29 
10 F 28 1 . 03 30 90 31 
11 F 32 1 . 1 29 77 25 
12 F 52 1 . 1 58 § 52 138 § 43 
13 F 25 1 37 § 112 § 26 
14 F 38 1 32 97 25 
15 F 42 1 27 76 26 
16 F 33 1. 2 § 66 § 48 295 § 42 
17 F 34 1 33 79 25 
18 F 43 1 27 73 26 
19 F 27 1 . 1 32 89 25 
20 F 31 1 36 § 77 26 
21 F 26 1 . 1 29 86 27 
22 F 48 1. 1 50 § 39 187 § 40 
23 F 54 1.06 27 95 27 
24 F 28 1. 06 35 92 28 
25 F 28 1. 03 32 73 25 
26 F 49 1 . 01 24 67 22 
27 F 39 1 . 01 25 71 23 
28 F 25 0.98 26 85 22 
29 F 24 1. 02 42 § 37 1 1 7 § 28 
30 M 36 1 63 § 40 149 § 30 
31 F 41 1 . 06 36 § 118 § 28 
32 F 29 1 27 67 25 
33 F 33 1. 02 29 82 26 
34 F 41 1 . 1 28 75 34 
35 F 25 1. 08 29 70 27 
36 F 58 1. 04 33 75 28 
37 F 33 1.06 32 84 28 
38 F 54 0.98 31 80 26 
39 F 48 1 . 1 9 § 34 93 25 
40 F 51 1. 19 § 31 67 29 
41 F 42 1. 06 28 78 29 
42 F 26 1. 04 27 80 26 
43 F 28 1 41 § 39 108 § 34 
44 F 43 0.98 29 76 27 
45 M 39 0.98 26 92 25 
46 F 28 0.98 27 72 26 
47 F 35 1. 04 27 77 25 
48 F 48 1 35 94 25 
49 F 54 1 . 02 29 73 24 
50 F 28 1.02 30 87 26 
------------------------------------------------------------










NO. SEX AGE INR APTT 1 : 1 KCT DRVVT 
MIX 
-------------------------------------------------------------
1 F 22 1 28 103 32 
2 F 31 1 . 1 1 28 155 30 
3 F 35 0.98 24 106 29 
4 F 53 1. 14 33 151 29 
5 F 51 1. 05 27 145 32 
6 F 43 1. 02 31 127 27 
7 F 33 1. 29 § 31 82 26 
8 F 25 1. 23 § 33 158 28 
9 F 26 1 . 1 2 44 § 206 30 
10 F 28 1. 05 32 189 29 
1 1 F 32 1 . 1 30 148 25 
12 F 52 1 . 1 63 § 55 >300 § 45 
13 F 25 1 40 215 § 28 
14 F 38 1 35 151 27 
15 F 42 1 28 122 28 
16 F 33 1. 2 70 § 59 >300 § 46 
17 F 34 1 33 185 26 
18 F 43 1 27 130 25 
19 F 27 1 . 1 32 175 26 
20 F 31 1 37 136 28 
21 F 26 1 . 1 30 180 29 
22 F 48 1. 2 54 § 41 >300 § 42 
23 F 54 1. 08 28 145 27 
24 F 28 1 . 06 36 135 32 
25 F 28 1 . 05 38 99 29 
26 F 49 1 . 03 26 74 27 
27 F 39 1.03 29 125 25 
28 F 25 0.98 26 132 24 
29 F 24 1. 04 45 § 244 § 30 
30 M 36 1 70 § 45 192 32 
31 F 41 1 . 09 39 216 § 28 
32 F 29 1 28 118 24 
33 F 33 1. 02 31 165 27 
34 F 41 1. 08 28 130 32 
35 F 25 1 . 1 30 105 28 
36 F 58 1. 06 34 145 30 
37 F 33 1.08 33 203 29 
38 F 54 1 32 159 27 
39 F 48 1 . 21 § 36 232 § 28 
40 F 51 1. 21 § 34 150 32 
41 F 42 1. 08 29 147 29 
42 F 26 1 .04 29 135 28 
43 F 28 1 • 02 42 163 30 
44 F 43 0.98 30 130 28 
45 M 39 0.98 28 132 26 
46 F 28 0.98 28 123 27 
47 F 35 1.06 27 142 26 
48 F 48 1 36 195 26 
49 F 54 1.02 30 135 24 
50 F 28 1.08 32 132 27 
--------------------------------------------------------------




TABLE 11. Confir1atory tests perfor1ed on suspected LA positives: 
(Al Platelet Neutralization Procedure and 
(Bl Tissue Thro,boplastin Inhibition test. 
No. PNP SALINE DIFFER- : TTI CONTROL RATIO TTI CONTROL RATIO 
CONTROL ENCE : 1: 50 1: 500 
12 59 74 15 C 56 30 1.87 120 56 2 .14 
16 60 75 15 C 57 29 1. 97 127 61 2.08 
22 40 47 C 66 32 2.06 129 54 2.39 
29 39 42 3 NC 30 26 1. 15 65 50 1.3 
30 43 59 16 C 49 30 1.63 100 58 1. 72 
43 ND 32 24 1.33 71 46 1.54 
--------------------------------------------------------------------------------------
C : Correction 
NC : No correction 
ND : Not done 
The Tissue Thromboplastin Inhibition test at the 1:50 
dilution confirmed 5 of the 6 cases, while all the samples 
at 1:500 dilution were positive (>1.3). Coagulation factor 
assays produced non-parallel curves on all samples as 
addition confirmation of the nature of the inhibitors. 
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There were 5 out of range INR (10%) results in the PPP group 
but only no. 16 corresponded with a positive LA. In the 
filtered group, 4 (8%) were out of range showing no 
correlation with LA positivity. 
4.4 ANTICARDIOLIPIN ANTIBODIES 
The IgG and IgM anticardiolipin antibody levels determined 
by ELISA assay, were performed on single serum samples. The 
values are tabulated (Table 12) and the levels demonstrated 
graphically in Figures 2 and 3. 
Three individuals tested positive by VDRL at a low titre of 
1/2 but all were negative by FTA, demonstrating false 
biological positive tests for syphilis. 
4.5 CLINICAL CORRELATIONS 
A history of clinical complications reported in association 
with LA and/or ACA, namely repeated abortions, venous and 
arterial thromboses and other associated problems, was 
evaluated. This information was extracted partly from a 
database maintained on some of the SLE patient group by the 
Department of Rheumatology, Groote Schuur Hospital and by 
reviewing hospital records. The information is summarized 
in Table 13. The six LA positive patients with SLE and all 
moderately elevated ACA levels are indicated on the table. 
Six patients were found to have a history of two or more 
abortions; one patient had two episodes of deep vein 
thrombosis of the leg and one patient a right external 
jugular vein thrombosis. There was one case of myocardial 
infarction, two cases of neuropsychiatric disorders and one 
case each of thrombophlebitis and pulmonary hypertension. 
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Table 12. IgG AND IgH ANTICARDIOLIPIN ANTIBODIES (ACA) 
LEVELS AND VDRL POSITIVE RESULTS IN SLE GROUP. 
-----------------------------------------------------------
No. SEX AGE ACA Ab ACA Ab VDRL 
IgG LEVEL IgM LEVEL 
-----------------------------------------------------------
1 F 22 25 M 26 M 
2 F 31 17 M 25 M 
3 F 35 0 23 M 
4 F 53 56 M 22 M 
5 F 51 20 M 17 M 
6 F 43 13 L 13 M 
7 F 33 3 11 M 
8 F 25 0 6 L 
9 F 26 6 L 14 M POS 1/2 
10 F 28 20 M 30 M 
11 F 32 5 5 L 
12 F 52 6 L 13 M 
13 F 25 5 11 M 
14 F 38 10 L 5 L 
15 F 42 28 M 10 M 
16 F 33 6 L 12 M 
17 F 34 4 10 M 
18 F 43 5 6 L 
19 F 27 5 42 M 
20 F 31 33 M 14 M 
21 F 26 13 L 13 M 
22 F 48 50 M 10 M 
23 F 54 0 1 
24 F 28 0 3 
25 F 28 5 9 M 
26 F 49 0 0 
27 F 39 0 0 
28 F 25 0 0 
29 F 24 48 M 10 M 
30 M 36 0 35 M 
31 F 41 28 M 0 
32 F 29 12 L 33 M 
33 F 33 7 L 33 M POS 1/2 
34 F 41 0 0 
35 F 25 5 0 
36 F 58 3 2 
37 F 33 0 0 
38 F 54 0 9 M 
39 F 48 5 39 M POS 1/2 
40 F 51 0 1 
41 F 42 0 0 
42 F 26 4 4 L 
43 F 28 0 0 
44 F 43 0 0 
45 M 39 6 L 3 
46 F 28 0 0 
47 F 35 0 34 M 
48 F 48 0 2 
49 F 54 0 0 
50 F 28 0 0 
-----------------------------------------------------------
f Low ( L): 9 5 
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A positive association with the presence of lupus anti-
coagulants was noted in two patients in the SLE study group. 
A history of neuropsychiatric disorder was recorded in 
patient no. 12 and a history of three pregnancies ending in 
spontaneous abortion in patient no. 43. 
49 
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Table 13. THE CLINICAL COMPLICATIONS: ABORTIONS, THROMBOTIC 
EVENTS AND OTHER PROBLEMS SEEN IN ASSOCIATION WITH 
LA POSITIVITY AND MODERATE LEVELS OF ACA. 
NO. SEX LA IgG IgM PREG ABORT VENOUS ARTERIAL ASSOCIATED PROBLEMS 
ACA ACA THROMB THROMB 
1 F M 
2 F M 
3 F 
4 F M 





10 F M 
11 F 
12 F LA 
14 F 
15 F M 




20 F M 
21 F 







29 F LA M 
30 M LA 













































































































0 OVT x 2 
0 
0 




























Frequency 6 2 
---------------------------------------------------------------------------------------------
§ denotes two or 1ore abortions 
CHAPTER 5 
DISCUSSION 
Studies on lupus anticoagulants have been hampered by a 
variety of problems in the preparation, transportation and 
storage of samples and the lack of standardized diagnostic 
procedures. This has favoured the wide spread use of the 
solid phase anticardiolipin assay as an alternative. The 
ACA assay is not subject to the same inherent handling 
problems and this facilitates its use in large population 
surveys, where associations occurring in patients with 
antibodies to phospholipids have been confirmed. However, 
the LA tests and ACA assay do not detect the same 
abnormality and therefore, it is advisable to perform both 
procedures. Laboratories offering this service need to be 
proficient in providing the most sensitive and reliable 
tests available. 
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In the design of this project, the above issues were 
addressed. The 1983 ICTH criteria for the laboratory 
diagnosis of lupus anticoagulants as recommended by Green et 
a7, 66 were strictly applied using a prolonged APTT 
screening test as a primary requirement. General 
Diagnostics auto-APTT reagent used routinely in this study, 
has been shown to be one of the most sensitive reagents in 
detecting lupus anticoagulants. 68 Routine use of insensitive 
agents can lead to underdiagnosis of lupus anticoagulants. 
5.1 NORMAL RANGE 
Tests and assays performed on forty control subjects 
provided values and times similar to published data. Use of 
standardized methodology and reagents of the same batch or 
lot numbers throughout the study, permitted subsequent 
evaluation of the two test groups on the basis of out of 
range values derived from the normal range. 
Filtering of plasma produced a significant prolongation of 
the mean kaolin clotting time only. This is attributed 
directly to the removal of platelets as shown by an equally 
significant fall in the mean platelet count of the post-
filtration samples. The increased coefficient of variation 
(CV) noted in the filtered KCT, highlights the need for 
meticulous attention to procedural detail to ensure adequate 
removal of platelets and a meaningful increase in test 
times. 
5.2 ABNORMAL CONTROL GROUP 
Evaluation of seven patients who had previously tested 
positive for LA, served as a useful exercise in determining 
the effectiveness of the test procedures. The presence of 
strong lupus anticoagulants were confirmed in six of the 
seven cases using approved ICTH criteria. The APTT 
screening procedure was most sensitive detecting 6 (85%) 
while the KCT was abnormal in 5 (71%) and the DRVVT in 4 
(57%). The INR being marginally abnormal in 2 (28%) was the 
least sensitive. It is interesting that case no. 7, which 
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was interpreted as LA negative, had the most prolonged 
DRVVT, confirming the heterogeneity of results in testing 
for lupus anticoagulants. 
All seven patients had confirmed SLE and it is important to 
note that cases 3, 5 and 6 were receiving corticosteroid 
therapy at the time of testing without causing a loss of LA 
activity. 
A retrospective analysis of the data using KCT and DRVVT 
ratios as described by Machin et al in 1991, 87 reduces the 
cut-off level considerably and increases the sensitivity 
threshold, with 6 abnormal and one borderline KCT and 5 
abnormal DRVVT results. Use of the KCT or DRVVT ratio are 
calculations that have merit in a laboratory where tests for 
the detection of LAs are seldom performed or where a normal 
range, applicable to local conditions, has not been 
established. The calculation based on a control time and 
patient value, is readily performed and the interpretation 
unambiguous. 
5.3 SLE STUDY GROUP 
Lupus anticoagulants were proven in six cases (12%) using 
platelet poor plasma and ICTH criteria. This is a low 
percentage for a high risk population of systemic lupus 
erythematosus patients by modern standards of investigation. 
In an analysis of 21 reported series (comprising over 1100 
patients with SLE), Love and Santoro 9 0 found an average 
prevalence of 34% for lupus anticoagulant. When series that 
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included only unselected or consecutive patients were 
considered separately, the frequency of LA was slightly, al-
though significantly, lower (28%). This prevalence figure 
is still appreciably higher than the widely quoted figure of 
10% reported by earlier estimates based on fewer patients. 
The relatively low frequency of LA in this series may be 
attributed to a number of reasons: 
1. The patient population was selected by excluding those 
who were receiving corticosteroids or other immuno-
suppressive drugs or who were on long-term 
anticoagulant therapy. By this selection, patients 
with active disease were not included in the sample and 
a bias may have resulted in the detection of fewer 
positive LA and ACA. 
2. The 1983 ICTH criteria used for the diagnosis of LA are 
rigid and poses restraints on evaluation and acceptance 
of newer sensitive test procedures. 
3. From previous experience in our laboratory, it was 
found that the APTT screening procedure should be 
prolonged by at least 5 seconds above the upper limit 
of normal so that mixing studies could be adequately 
evaluated. Several weak LA may have thus gone 
undetected. This is apparent when considering the 10 
abnormal APTT and 8 abnormal KCT results in this study 
with only six cases of LA confirmed. 
54 
4. Use of a 1:1 mixture of patient to normal plasma, was 
the ICTH recommendation. Recent research has shown a 
4:1 ratio is preferable as it does not swamp weaker 
inhibitors.11 
5. The source of normal control plasma used to perform 
mixing studies is crucial. Kaczor et a7 showed that 
Verify Normal R plasma (General Diagnostics) which was 
used in this study, was inferior when compared to 
another commercially prepared reagent (Helena ARP R).7 1 
This difference may be especially apparent when 
evaluating minimally prolonged screening tests. 
6. Although generally accepted that LA are immediate 
acting inhibitors, Clyne and White 11 showed that 40% 
of LA require incubation to exhibit maximal 
anticoagulant activity and that some may not be 
detected if mixing studies are restricted to the 
preincubation phase. This aspect was not evaluated in 
the study. 
Comparing the PPP and filtered plasma study groups, shows 
that filtration reduced the sensitivity of all tests to 
detect lupus anticoagulants. The procedure is time-
consuming, adds expenditure with no additional benefit and 
could not be recommended for routine use. 
The lupus cofactor which causes a paradoxical prolongation 
of the mixture time (sometimes exceeding that of the initial 
APTT) was not detected in any of the specimens tested in 
this study. This cofactor effect was probably suppressed by 
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the use of 1:1 mixture ratios as it has usually only been 
reported in laboratories using a 4:1 ratio.1 71 
Confirmatory tests performed on plasma samples of suspected 
lupus anticoagulants analysed in Table 11, shows a similar 
trend in both PNP and TT! results. In patient no. 29, 
however, the PNP showed no correction while the TT! was 
positive only at the 1:500 dilution. This was presumably 
due to a low titre inhibitor, but as the tests are based on 
divergent principles, the value of performing both 
procedures in confirming suspected LA is endorsed. 
Misgivings have been expressed regarding the lack of 
specificity of the TT! test for LA,79 so but this was not, 
however, apparent in this study. 
Use of the INR can not be advocated as a sensitive screening 
procedure. In the PPP group, of the five out of range 
results, only one occurred in a LA confirmed case while non.e 
of the four in the filtered group showed a positive 
correlation. 
5.4 ANTICARDIOLIPIN ANTIBODIES 
The frequency of anticardiolipin antibodies in patients with 
SLE have varied widely from 21 to 63~ with a mean of 44%, as 
reported by Love and Santoro in a computer assisted search 
of the literature.go Discrepancies have arisen from 
differences in assay methodology as earlier work utilized 
markedly different methods. An international workshop 
addressed this issue in 1986, 91 resulting in standard-
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ization of the ELISA assay technique, including the use of 
fetal calf serum as blocking agent to prevent non-specific 
binding. Agreement on the definition of a positive result 
remained unsettled until the Kingston Anti-phospholipid 
Study (KAPS) Group published a special report in 1990 on the 
second international standardization workshop where the use 
of six standards to obtain semiquantitative measure of 
anticardiolipin activity of both IgG and IgM isotypes was 
proposed. 92 
The idea that titre or isotype (specifically IgG) of 
anticardiolipin may be important in determining which 
patients have thrombosis has received considerable attention 
of late. There is a strong association between high-titre 
anticardiolipin and a history of thrombosis.93 Several 
cases have been reported in which ACA titres have been shown 
to fluctuate markedly over time (with and without immuno-
suppressive therapy) and changes may be accompanied by 
alteration in antibody isotype.ss For this reason, it is 
questionable whether the clinical significance of antibody 
isotype or titre can be accurately assessed on the basis of 
a single test. 
One main drawback of the anticardiolipin test is its 
sensitivity, which can give rise to frequent false positive 
results (albeit that most such results are low positive).92 
IgM ACA assay is particularly prone to this fault and to 
nonspecific binding. It is, therefore, sensible to consider 
only moderate or high positive ACA test results (on repeated 
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testing) when attributing clinical associations to their 
occurrence. 
In the SLE group, 33 (66%) had at least one ACA isotype and 
17 (34%) had both IgG and IgM antibodies. If the low 
positive results are disregarded, the frequency of ACA 
positivity is 27 (54%) which is well within the reported 
range for patients with systemic lupus erythematosus. There 
were 10 moderate IgG (20%) and 26 IgM (52%); 9 (18%) were 
positive for both isotypes. Five of the six LA positive 
cases (83%) also had moderate IgM ACA levels and a two (33%) 
had moderate IgG positivity. 
5.5 CLINICAL ASSOCIATIONS 
The frequency of clinical complications in the SLE group was 
relatively low with 13 evaluable events occurring in 11 
patients (22%). This is less than the estimated one third 
of all patients with SLE in which complications can be 
expected. 
Associations were noted with a history of two or more 
abortions recorded in one patient with LA and in two with 
moderate IgM ACA. One myocardial infarction and one patient 
with pulmonary hypertension had IgM ACA in the moderate 
range and one case of LA with moderate IgM levels had a 
history of a neuropsychiatric disorder. 
The importance of moderately elevated IgM ACA levels in this 
study, is borne out by a strong correlation between LA 
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positivity and IgM antibodies (83%) and to the occurrence of 
this antibody isotype in 38% of patients with clinical 
complications. It is highly probable that if SLE patients 
had not been excluded from this study on the grounds of 
current immunosuppressive therapy, a greater number of 
symptomatic patients, with associated clinical complications 
could have been evaluated. Corticosteroids have a 
suppressive effect on lupus anticoagulants, but to a lesser 
extent on anticardiolipin antibodies.so This is due in part 
to the sensitivity of the ACA ELISA technique and further 
highlights the versatility of this test procedure. It is 
recommended that ACA testing be introduced routinely in the 
evaluation of patients with SLE, irrespective of concurrent 
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anticoagulant or immunosuppresive therapy. r II ~ 
CHAPTER 6 
CONCLUSIONS 
In concluding this investigation of lupus anticoagulants, it 
is necessary to formulate recommendations on the most 
appropriate investigative procedure in a patient in whom 
this conditio~ is suspected. 
1. Double centrifugation of patient plasma is a step that 
needs to be adopted to enhance detection of minimally 
prolonged APTTs. 
2. A normal range can be used to determine upper limits 
provided reagents, methodologies and apparatus remain 
constant. Alternatively, recently advocated test ratios 
which rely on control times to quantify results, with a 
published cut-off values, are preferable where a normal 
range is lacking. 
3. An APTT screening test using a reagent with proven 
sensitiv_ity to detect weak lupus anticoagulants, is the best 
primary test to perform. The procedure is automated and 
routin~ly performed. The KCT is equally sensitive but 
usually a manual method, as the tecently described automated 
KCT 12 requires a programmable centrifugal coagulation 
analyzer to read the clotting times which are not available 
in all coagulation laboratories. 
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4. Mixing studies should be performed on all prolonged 
APTT results. A 4:1 ratio of patient to normal plasma 
recommended by most researchers today to avoid swamping 
weaker inhibitors, although not tested in this study, 
requires serious consideration. 
5. Source of normal plasma used to perform mixing studies 
must be platelet poor. Manufacturers specifications should 
be examined to ensure that steps are taken to remove 
platelets from pooled plasma lots (preferably by filt-
ration), as residual platelet fragments may neutralize 
weaker LA. 
6. In our hands, the dilute RVVT is not sufficiently 
sensitive to be advocated for routine screening or 
confirmation. However, it is occasionally the only test 
time to be prolonged in the presence of LA. 
7. The PNP and TT! are both equally effective as 
confirmatory test. The 1:500 dilution of TT! seems 
marginally more sensitive but a tendency to false positive 
results has challenged its specificity.as 
8. Anticardiolipin antibody assays should be performed on 
all positive and suspected cases of LA as this test detects 
a different antiphospholipid epitope. Single estimations 
are not easily evaluated, and as in any serological 
investigation, a follow-up specimen is recommended. 
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